PolyMedix is committed to treating the underlying causes of serious, life threatening acute diseases by being the leader in developing novel therapeutic drugs for membrane protein and protein: protein targets. PolyMedix has a proprietary computational technology platform that we use in developing product candidates. PolyMedix has used this platform to initially focus on developing a line of novel anti-infective drugs and materials, as well as our anticoagulant antagonist program we call heptagonists. These programs will be followed by other products that uniquely treat serious medical conditions.

Our product candidates have not been approved by the U.S. Food and Drug Administration or any international regulatory agency.

return to top ^